- Home
- CATX vs CERS Comparison
CATX vs CERS Comparison
Compare CATX & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATX
- CERS
- Stock Information
- Founded
- CATX 1983
- CERS 1991
- Country
- CATX United States
- CERS United States
- Employees
- CATX N/A
- CERS N/A
- Industry
- CATX Medical/Dental Instruments
- CERS EDP Services
- Sector
- CATX Health Care
- CERS Technology
- Exchange
- CATX Nasdaq
- CERS Nasdaq
- Market Cap
- CATX 239.0M
- CERS 255.0M
- IPO Year
- CATX N/A
- CERS 1997
- Fundamental
- Price
- CATX $3.27
- CERS $1.28
- Analyst Decision
- CATX Strong Buy
- CERS Strong Buy
- Analyst Count
- CATX 11
- CERS 2
- Target Price
- CATX $12.90
- CERS $3.50
- AVG Volume (30 Days)
- CATX 696.8K
- CERS 1.1M
- Earning Date
- CATX 11-11-2025
- CERS 10-29-2025
- Dividend Yield
- CATX N/A
- CERS N/A
- EPS Growth
- CATX N/A
- CERS N/A
- EPS
- CATX N/A
- CERS N/A
- Revenue
- CATX $1,235,000.00
- CERS $192,510,000.00
- Revenue This Year
- CATX N/A
- CERS $22.02
- Revenue Next Year
- CATX N/A
- CERS $9.32
- P/E Ratio
- CATX N/A
- CERS N/A
- Revenue Growth
- CATX N/A
- CERS 13.25
- 52 Week Low
- CATX $1.60
- CERS $1.12
- 52 Week High
- CATX $14.19
- CERS $2.24
- Technical
- Relative Strength Index (RSI)
- CATX 44.58
- CERS 50.27
- Support Level
- CATX $3.02
- CERS $1.17
- Resistance Level
- CATX $3.74
- CERS $1.27
- Average True Range (ATR)
- CATX 0.25
- CERS 0.06
- MACD
- CATX -0.01
- CERS -0.00
- Stochastic Oscillator
- CATX 29.52
- CERS 58.33
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.